Recent publications from the COVID-19 Global Rheumatology Alliance and from France's consumer interest association UFC-Que Choisir hinted at global drug supply shortages through different scopes and methods.The first, results from the alliance's 9,000-person survey, was presented at the annual ACR Convergence 2020 late last week and reported that 6.2% of global respondents were unable to receive their antimalarial, rheumatic disease treatments (eg, hydroxychloroquine and chloroquine) because of pharmaceutical shortages.Hydroxychloroquine has been prescribed to treat COVID-19, with little proven success, but its use has led to shortages for the diseases for which it has been approved.The second is an analysis of 140 drugs of major
Read more on cidrap.umn.edu